Related Experiment Video

Updated: Aug 10, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

p53, a potential target for tumor-directed T cells

H W Nijman1, S H Van der Burg, M P Vierboom

  • 1Department of Immunohaematology and Blood Bank, University Hospital, Leiden, The Netherlands.

Immunology Letters
|May 1, 1994
PubMed

Insights

Researchers identified specific wild-type p53 peptides that bind strongly to HLA-A*0201, leading to the generation of cytotoxic T lymphocyte (CTL) responses. These findings support targeting p53 for cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Tumor-specific antigens can trigger cytotoxic T lymphocyte (CTL) responses, offering a basis for cancer immunotherapy.
  • Self-proteins like p53 are potential targets for T cell-mediated anti-cancer immunity, as suggested by responses to melanoma-associated antigens.
  • Identifying specific epitopes is crucial for developing p53-targeted T cell therapies.

Purpose of the Study:

  • To identify wild-type p53 peptides with high affinity for the HLA-A*0201 molecule.
  • To generate and characterize CTL responses against these p53 peptides.

Main Methods:

  • Utilized MHC peptide-binding and peptide competition assays to screen p53 peptides for HLA-A*0201 binding affinity.
  • Generated CTLs specific for high-affinity p53 peptides.

Main Results:

  • Identified several wild-type p53 peptides exhibiting high affinity for the HLA-A*0201 molecule.
  • Successfully generated CTLs recognizing four high-affinity p53 peptides.

Conclusions:

  • The study successfully identified p53-derived peptides that can elicit CTL responses in the context of HLA-A*0201.
  • These findings provide a foundation for developing novel cancer immunotherapies targeting wild-type p53.

More Related Videos

Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.